DEBORAH FERGUSON: Open Payments
NPI 1952079709 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,155 in 51 payments from 9 companies in 2025. Trend: 2023 $243 · 2024 $1,272 · 2025 $1,155
Food & beverage: $1,155
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $250 |
| E.R. Squibb & Sons, L.L.C. | 8 | $219 |
| Otsuka America Pharmaceutical, Inc. | 9 | $194 |
| ABBVIE INC. | 7 | $148 |
| Teva Pharmaceuticals USA, Inc. | 5 | $108 |
| Almatica Pharma LLC | 5 | $95 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $79 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: INGREZZA, COBENFY, REXULTI, VRAYLAR, LOREEV XR, AUSTEDO XR, CAPLYTA, Auvelity.
Industry payments across TX — which companies pay providers there.
